


FORM 100-1 (2/89) Adapted



## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

APPLICANT DOCKET NO. 01994	SERIAL NO. 08/215,030	FILING DATE March 18, 1994
APPLICANT Lawrence Tamarkin et al.		GROUP 1806

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,740,589	04/26/88	Moreno			
	AB	3,145,144	08/18/64	Ando			
	AC	3,269,912	08/30/66	Grase			
	AD	3,577,523	05/04/71	Stolar et al.			
	AE	4,069,313	01/17/78	Woodhour et al.			
	AF	3,983,228	09/28/76	Woodhour et al.			
	AG	3,531,565	09/29/70	Webb et al.			
	AH	3,149,036	09/15/64	Woodhour et al.			
	AI	3,399,263	08/27/68	Strazdins et al.			
	AJ	4,657,763	04/14/87	Finkelstein			
	AK	4,330,530	05/18/82	Baker			

RECEIVED  
JUN 28 1994  
GROUP 1800

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.	
	AL	WO 9102078	2/21/91	PCT			
	AM						
	AN						
	AO						

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," <i>The Journal of Experimental Medicine</i> , Vol. 170, pages 1015-1020 (1989)
	AR	Lanzavecchia, "Identifying Strategies for Immune Intervention," <i>Science</i> , Vol. 260, pages 937-944 (1993)
	AS	Paciotti, et al., "Interleukin 2 differentially effects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line <i>in vitro</i> and <i>in vivo</i> ," <i>Anti-Cancer Research</i> , Vol. 8, pages 1233-1240 (1988)
	AT	Paciotti, et al., "Interleukin 1 differentially synchronizes estrogen dependent and estrogen-independent human breast cells in G <sub>0</sub> /G <sub>1</sub> phase of the cell cycle," <i>Anti-Cancer Research</i> , vol. 11, pages 25-32 (1991)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. ROCKETT

SERIAL NO.

FILING DATE

01994-0020

08/033,385

March 18, 1993

APPLICANT

GROUP

Lawrence Tamarkin

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	4,339,437	07/13/82	Rosenberg et al.			
	BB	4,177,263	12/04/79	Rosenberg et al.			
	BC	4,053,587	10/11/77	Davidson et al.			
	BD	4,977,286	12/11/90	Nicolaou et al.			
	BE	5,017,687	05/21/91	Vahlne et al.			
	BF	4,812,556	04/14/89	Vahlne et al.			
	BG	4,880,750	11/14/89	Francoeur			
	BH	5,035,995	07/30/91	Taguchi et al.			
	BI	4,882,423	11/21/89	Taguchi et al.			
	BJ	4,906,564	03/06/90	Lyon et al.			
	BK	5,019,497	05/28/91	Olsson			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO.
	BL						
	BM						
	BN						
	BO						


## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	BP	Paciotti, et al., "Interleukin 1 directly regulates hormone-dependent human breast cancer cell proliferation <i>in vitro</i> ," <i>Mol. Endocrinol.</i> , Vol. 2, pages 459-464 (1988)
	BR	Coulombe et al., "Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chloropheniramine-induced Phospholipidosis," <i>Journal of Histochemistry and Cytochemistry</i> , Vol. 37, No. 2, pages 139-147 (1989)
	BS	Hashimoto et al., "Action Site of Circulating Interleukin-1 on the Rabbit Brain," <i>Brain Research</i> , Vol. 540, pages 217-223 (1991)
	BT	Ohmann et al., "Expresion of Tumor Necrosis Factor- $\alpha$ Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," <i>Lymphokine Research</i> , Vol. 9, No. 1, pages 43-58 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



# LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTN: DOCKET NO. 01994-0020	SERIAL NO. 08/033,385	FILING DATE March 18, 1993
APPLICANT Lawrence Tamarkin		GROUP

RECEIVED  
JUN 20 1994  
GROUP 1

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	4,753,873	06/28/88	Beltz et al.			
	CB	4,744,760	05/17/88	Molday			
	CC	4,624,923	11/25/86	Margel			
	CD	3,651,211	03/21/72	Gillchriest et al.			
	CE	2,768,958	10/30/56	Stewart et al.			
	CF	2,785,153	03/12/57	Locke et al.			
	CG	3,819,820	06/25/74	Lorina et al.			
	CH	5,112,606	5/12/92	Shiosaka et al.			
	CI						
	CJ						
	CK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO.
	CL						
	CM						
	CN						
	CO						

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	CP	
	CR	
	CS	
	CT	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.